Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28899645 | 0.86 | ALDH1A1 (0.34) | NAAAOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL28899706 | 0.69 | OPRM1 (0.43) | CHRM3NAAAOPRM1OPRD1OPRK1 | |
| SCHEMBL18342994 | 0.67 | ALDH1A1 (0.40) | CHRM3 | |
| SCHEMBL30632554 | 0.67 | ALDH1A1 (0.40) | OPRK1 | |
| SCHEMBL28899643 | 0.67 | OPRK1 (0.40) | NAAAOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL547562 | 0.66 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5815457 | 0.66 | CHRM2 (0.40) | CHRM3 | |
| SCHEMBL547417 | 0.66 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL16398595 | 0.62 | POLB (0.40) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7642789 | 0.61 | EPHX1 (0.53) | NAAAHTR2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |